Hideki Nakayama

8PUBLICATIONS
18CO-AUTHORS
Tumour immunologyMolecular targetsOral and maxillofacial surgeryApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 24, 2026
Increased density of CD103-positive tissue-resident memory T cells predicts favorable response to immunotherapy in oral cancers.

|Aug 11, 2026
SMAD4 Expression and Its Association With Treatment Resistance and Clinical Outcomes in Oral Squamous Cell Carcinoma Treated With Preoperative Chemoradiotherapy.

|Jul 11, 2025
Pterygomandibular raphe invasion as a novel grading and prognostic factor for squamous cell carcinoma of buccal mucosa: a retrospective study with propensity score matching.

Ryoji Yoshida, Riu Lin, Keisuke Yamana

|Apr 02, 2022
E3 Ubiquitin Ligase Riplet Is Expressed in T Cells and Suppresses T Cell-Mediated Antitumor Immune Responses.

Asuka Iwamoto, Hirotake Tsukamoto, Hideki Nakayama

|Feb 15, 2022
Air Plasma-Activated Medium Evokes a Death-Associated Perinuclear Mitochondrial Clustering.

Manami Suzuki-Karasaki, Takashi Ando, Yushi Ochiai

|Jan 11, 2022
The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma.

Rin Liu, Satoru Shinriki, Manabu Maeshiro

Pageof 2

Frequent Collaborators

3 joint publications

Kenta Kawahara

3 joint publications

Ryoji Yoshida

2 joint publications

Akiyuki Hirosue

2 joint publications

Junki Sakata